• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

How continuous glucose monitors have transformed the diabetes landscape

January 25, 2021 By Brian Buntz

G6
Dexcom G6 from Dexcom

Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.

FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.

“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.

But the fingerstick blood glucose monitor provides more of a snapshot than a moving picture. “About 15 years ago, professional continuous glucose monitoring was introduced. Initially, it was just endocrinologists [who used it], and we used it in what we called a retrospective manner.” Endocrinologists had patients wear CGMs for initially three days and later 10 days as the technology evolved. After that point, “we looked at the data to recognize patterns for people who were on insulin.”

Professional CGMs later morphed into personal CGMs. “Initially, the main emphasis was to avoid hypoglycemia,” Bogdanovics said. For patients with type 1 diabetes, there is the risk of so-called “hypo unawareness,” where blood sugar levels fall to dangerous levels before a patient notices there is a problem. With a CGM, “an alarm would go off at 3 a.m. and you can avoid having a hypoglycemia emergency requiring glucagon,” he added.

As CGMs have evolved and become more user-friendly and long-lasting, people with diabetes are using them not just for hypoglycemia but overall blood glucose control. “This is anecdotal, but when we put patients on CGMs, their A1C’s tend to come down a couple of points,” Bogdanovics said, referring to the hemoglobin-based test that provides an estimate of blood sugar levels over the past three months.

One traditional challenge of A1C numbers — before CGMs were widely available — is that they only provide a long view of blood sugar. Two patients could have a moderately high A1C reading of 7, but one might have relatively stable blood sugar control while the other might have frequent peaks and valleys in glucose.

“That’s where this ‘time-in-range’ comes in,” Bogdanovics said, referring to CGMs ability to determine how often people with diabetes are in a specified blood glucose window. “We can avoid highs and lows, and have the blood-glucose average nice and tight.”

“The metric in diabetes since CGMs came out is starting to change,” Bogdanovics added. “It’s not just A1C — it’s how much of that time is spent in that target range.”

CGMs also allow people with diabetes to be better-informed in their insulin use. “Regardless of how you get your insulin — insulin pumping or multiple daily insulin injections — the most important thing is CGM,” Bogdanovics said. “It’s markedly better control, and less time with [blood-glucose] lows than an insulin pump with finger sticks or multiple injections with finger sticks.”

There are also a growing number of insulin pumps designed to work with CGMs. The Dexcom (NSDQ:DXCM) G6, for instance, supports the Tandem t:slim X2 insulin pump. “It gets real-time Dexcom CGM data, and it can anticipate that the blood sugar is actually going to drop below normal and slow down the rate of infusion.”

Similarly, if a patient’s CGM glucose reading is above normal, the pump can increase insulin infusion rate.

Another example of a CGM-insulin pump combo includes the Medtronic (NYSE:MDT) 670G and the t:slim X2. Eli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are also partnering on automated insulin delivery.

Bogdanovics would like to see broader use of CGMs in the future. “In my practice, 85% of anybody on insulin has a CGM, but if you look across the nation, the device penetration is well below 50% — probably somewhere around 35%,” he said. “There’s still a lot of room to improve the use of it.”

In the long run, though, Bogdanovics sees fingerstick-based blood glucose monitoring gradually fading away. “I think CGM is here to stay, and it’s improving,” he said.

The integration with smart devices, in particular, is a powerful tool, Bogdanovics said. Smart devices make it possible for parents, for instance, to keep track of their diabetic children’s glucose levels to ensure they don’t trend too high or low.

The technology is “taking off, but I think that we’ve just got to get the message out there,” Bogdanovics concluded.

Filed Under: Diabetes, Featured Tagged With: A1C, blood glucose monitoring, CDC, CGM, continuous glucose monitor, Diabetes, fingerstick, hypoglycemia, smartphone

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS